Sangamo Therapeutics, INC

Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection and its Nasdaq delisting request has been denied, leading to trading on the OTCQB.

Sangamo Therapeutics has filed for Chapter 11 bankruptcy and its stock now trades on the OTCID Basic Market, while a Nasdaq delisting appeal is pending.

Sangamo Therapeutics reported first quarter 2026 financial results, including a net loss of $31.0 million, while also announcing its common stock was delisted from Nasdaq and began trading on the OTCQB Venture Market.

Sangamo Therapeutics has received a delisting notice from Nasdaq due to a sustained low stock bid price and will transition to the OTCQB Venture Market.

Sangamo reported a wider FY25 net loss as it advances a rolling BLA for its Fabry gene therapy, but warned of severe funding risk with cash runway only into Q3 2026.

Sangamo Therapeutics, Inc. announced an underwritten public offering of common stock and warrants, expected to generate approximately $25.0 million in gross proceeds.

Sangamo Therapeutics reports significant financial challenges, including a Nasdaq delisting and substantial doubt about its ability to continue as a going concern, while advancing its neurology pipeline.

Sangamo Therapeutics reported a significant revenue decline and increased net loss for Q3 2025, raising substantial doubt about its ability to continue as a going concern, while also receiving a Nasdaq delisting extension.

Sangamo Therapeutics reports improved Q2 2025 financials driven by new collaborations but warns of substantial doubt about its ability to continue as a going concern.

Sangamo Therapeutics announces its Q1 2025 financial results, highlighting progress in neurology programs and ongoing efforts to secure additional funding amid going concern uncertainties.

Sangamo Therapeutics announced its Q3 2024 financial results, emphasizing a significant collaboration with Genentech and a potential accelerated approval pathway for its Fabry disease program.

Sangamo Therapeutics reported its Q2 2024 results, highlighting a strategic focus on neurology and a new licensing agreement, while also acknowledging substantial doubt about its ability to continue as a going concern.

Sangamo Therapeutics reports a net loss and expresses substantial doubt about its ability to continue as a going concern, even with recent collaboration agreements.

Sangamo Therapeutics is restructuring to focus on neurology, highlighting a novel AAV capsid for brain delivery and advancing preclinical programs.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reported a mandatory tax withholding transaction involving 1,630 shares.

Principal Accounting Officer Nikunj Jain reported the disposition of 1,919 shares to satisfy mandatory tax withholding obligations.

SVP-Chief Development Officer Nathalie Dubois-Stringfellow disposed of 4,036 shares to satisfy mandatory tax obligations.

Scott B. Willoughby, SVP and Chief Legal Officer of Sangamo Therapeutics, reported a mandatory tax withholding transaction of 4,036 shares.

CEO Sandy Macrae disposed of 12,613 shares of Sangamo Therapeutics to satisfy mandatory tax withholding obligations related to RSU vesting.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc., reported a sale of common stock on April 22, 2026.

Sangamo Therapeutics is holding its annual stockholder meeting to vote on director elections, executive compensation, and an amendment to its equity incentive plan.

Sangamo Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 4, 2024, to vote on key proposals including the election of directors, executive compensation, equity incentive plan amendments, and an increase in authorized shares.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 9.75% of Sangamo Therapeutics, Inc. common stock as of March 31, 2026.

Wasatch Advisors LP filed an Amendment No. 9 to Schedule 13G, reporting a 2.1% beneficial ownership stake in Sangamo Therapeutics Inc. as of September 30, 2025.

Wasatch Advisors LP, an investment adviser, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.2% in Sangamo Therapeutics, Inc. as of March 31, 2025.

Wasatch Advisors LP has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Sangamo Therapeutics, Inc. as of December 31, 2024.